Journal of neurology, neurosurgery, and psychiatry
-
J. Neurol. Neurosurg. Psychiatr. · Mar 2020
Multicenter StudyMinimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis.
This study aimed to define the minimal evidence of disease activity (MEDA) during treatment that can be tolerated without exposing patients with relapsing-remitting multiple sclerosis at risk of long-term disability. ⋯ Early marginal MRI activity of one to two new T2 lesions, in the absence of both relapses and CELs, is associated with a minor risk of future disability, thus representing a simple and valuable definition for MEDA.
-
J. Neurol. Neurosurg. Psychiatr. · Mar 2020
Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia.
There are few validated fluid biomarkers in frontotemporal dementia (FTD). Glial fibrillary acidic protein (GFAP) is a measure of astrogliosis, a known pathological process of FTD, but has yet to be explored as potential biomarker. ⋯ Raised GFAP concentrations appear to be unique to GRN-related FTD, with levels potentially increasing just prior to symptom onset, suggesting that GFAP may be an important marker of proximity to onset, and helpful for forthcoming therapeutic prevention trials.
-
J. Neurol. Neurosurg. Psychiatr. · Mar 2020
Historical ArticleOne hundred years of shared interest.